Roche Highlights 5-year Analysis from P-III (POLARIX) Study of Polivy (Polatuzumab Vedotin) for Diffuse Large B-Cell Lymphoma (DLBCL) at ASH 2024
Shots:
- The P-III (POLARIX) trial assessed Polivy + R-CHP vs rituximab, cyclophosphamide, doxorubicin, vincristine & prednisone (R-CHOP) in treatment-naïve DLBCL patients (n=879)
- The 5yrs. exploratory analysis showed a +ve OS trend favoring the combination in ITT population & an improvement in the reduction of death risk from 3yrs. data; Polivy + R-CHP required ~25% less follow-up treatments (38.3% vs 61.7%). Further OS differences may emerge & another 2yrs. follow-up will continue
- Furthermore, PFS & DFS benefits were observed that aligned with 3yrs. data; lymphoma-related deaths were lower with Polivy + R-CHP (9.0% vs 11.4%). Expanded cohort data (n=1,000; incl. Chinese patients) was similar to ITT population
Ref: Roche | Image: Roche
Related News:- US FDA’s Accepts sBLA of Roche's Columvi (Glofitamab) Combination to Treat R/R Diffuse Large B-Cell Lymphoma (DLBCL)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
